Canvax Biotech has hosted in its headquarters the last Technical Committee of the SNC-Integra project, developed by a biotechnology cluster of Andalusian companies, led by Laboratorios Rovi and where, together with Canvax Biotech,there are participating companies such as VivaCell, Bionaturis, GMV, Vivia Allosterics and Vivia Biotech.
This technical committee presented the main conclusions of this project, which, as noted, has allowed the development of different lines of work related to the Central Nervous System. In addition, various diseases have been covered such as schizophrenia, Alzheimer, Gaucher’s Disease or primary lymphoma. Moreover, the consortium has worked in the search for new molecules to open new drug therapies for the treatment of these diseases.
For more information, read the full article here.